Cargando…

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

BACKGROUND: The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ren‐Shu, Liu, Jie, Deng, Yao‐Tiao, Wu, Xin, Jiang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160813/ https://www.ncbi.nlm.nih.gov/pubmed/35191609 http://dx.doi.org/10.1002/cam4.4613

Ejemplares similares

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
por: Long, Zuoyao, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
por: Imai, Reiko, et al.
Publicado: (2018)

PA02.03. Pharmaceutical standardization of Ropya raj rasa
por: Agrawal, Sachin, et al.
Publicado: (2013)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
por: Gounder, Mrinal M., et al.
Publicado: (2020)

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
por: Liu, Jiayong, et al.
Publicado: (2021)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
por: Cai, Meng, et al.
Publicado: (2022)

OA02.03. Healers in the context of culture: The ashtavaidya tradition of Kerala, South India.
por: Leela, PU
Publicado: (2013)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions
por: Boyce-Fappiano, David, et al.
Publicado: (2022)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

OA02.03. Nutrient biomarker patterns and rates of cognitive decline in dementia-free elders
por: Bowman, G, et al.
Publicado: (2012)

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
por: Akagi, Kiwamu, et al.
Publicado: (2021)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence
por: Spałek, Mateusz Jacek, et al.
Publicado: (2022)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany
por: KRAMB, Felix, et al.
Publicado: (2022)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma
por: Van Tine, Brian A., et al.
Publicado: (2019)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
por: Zou, Hanhui, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

Liver Transplantation in Locally Unresectable, Undifferentiated Embryonal Cell Sarcoma
por: Babu, Benoy I., et al.
Publicado: (2021)

Definitive Local Therapy Is Associated with Improved Survival in Metastatic Soft Tissue Sarcomas
por: Reddy, Vishruth K., et al.
Publicado: (2021)

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort
por: Wu, Hongyang, et al.
Publicado: (2022)

Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas
por: Testa, Stefano, et al.
Publicado: (2022)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Guo, Wenbo, et al.
Publicado: (2020)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Treatment Strategies for Metastatic Soft Tissue Sarcomas
por: Wiltink, Lisette M., et al.
Publicado: (2021)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
por: Deutschmann, Christine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hbj0aipfcs5m11snon8sajqqh0